BioSpace News Archive

Eli Lilly and Company reported that its Emgality met the primary and all key secondary endpoints in its Phase III CONQUER study for chronic and episodic migraine.

Sosei Group Corporation inked a strategic multi-target partnership with Takeda Pharmaceutical to find, develop and commercialize small molecules and biologics that modulate G protein-coupled receptor targets. The initial focus will be on gastrointestinal targets.

CELLINK AB has entered an agreement with the owners of cytena GmbH to acquire all cytena shares for a purchase price of 30.25M euros.

AI Design enables new bispecific small molecule modality

Oncoceutics, Inc., announced a collaboration with the National Cancer Institute funded Pediatric Preclinical Testing Consortium to enable tumor type selection for ONC201 clinical trials in pediatric oncology beyond diffuse midline gliomas.

Cyclone® 70 will be used as a high energy, high intensity proton “driver” for a large science project for rare isotopes

New ‘Vilnius-Made’ method reduces DNA testing costs by 90%, while the city’s long-standing tradition of life sciences further position Lithuanian Capital as emerging European hub of international scientific development

Funding will finance further development and IVD-CE marking of the company’s first molecular POC (Point of Care) platform, based on Pulse Controlled Amplification (PCA) technology

According to a BioSpace poll, approximately 86% of life science respondents are on the verge of job burnout. Are you one of the 86%? Does this mean you need to start looking for a new job? This is definitely one of your options. Start here to look at all of the great opportunities out there in the life science industry!

Silence Therapeutics, PLC, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce that Jørgen Wittendorff has been appointed to the new role of Head of Manufacturing at Silence Therapeutics.